[Gastric protection and treatment with low-dose aspirin].
Agustí-Escasany
Antònia
A
Fundació Institut Català de Farmacologia, Servicio de Farmacología Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Vallano-Ferraz
Antonio
A
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000367:Age Factors; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D018849:Controlled Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D015201:Meta-Analysis as Topic; D016017:Odds Ratio; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D054328:Proton Pump Inhibitors; D012306:Risk; D012307:Risk Factors; D013270:Stomach / Q000187:drug effects*; D013276:Stomach Ulcer / Q000150:complications / Q000517:prevention & control; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D013608:Tablets, Enteric-Coated; D064747:Lansoprazole; D009853:Omeprazole; D001241:Aspirin